CRANAD-2

• Description:

  CRANAD-2 is a near-infrared (NIR) Aβ plaque-specific fluorescent probe. CRANAD 2 penetrates the blood brain barrier and has a high affinity for Aβ aggregates with a Kd of 38 nM[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319

• Target:

  Amyloid-β

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/cranad-2.html

• Purity:

  98.0

• Solubility:

  DMF : 2 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 2.08 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  CN(C)C(C=C1)=CC=C1/C=C/C2=O[B+3]([F-])([F-])O=C(/C=C/C3=CC=C(N(C)C)C=C3)[CH-]2

• Molecular Formula:

  C23H25BF2N2O2

• Molecular Weight:

  410.26

• Precautions:

  H315, H319

• References & Citations:

  [1]Ran C, et al. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits. J Am Chem Soc. 2009 Oct 28;131 (42) :15257-61. |[2]Ran C, et al. Non-conjugated small molecule FRET for differentiating monomers from higher molecular weight amyloid beta species. PLoS One. 2011 Apr 29;6 (4) :e19362.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1193447-34-5]